We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed substantial positive momentum: meaningful revenue growth (largely license-related), improved net loss, strong cash runway, and multiple encouraging clinical readouts and development milestones (notably WVE-007 visceral fat and VMR improvements, advancing WVE-007 into Phase IIa, and WVE-006 demonstrating therapeutically relevant MAAT and regulatory path potential). Headwinds include rising operating expenses, remaining net losses, regulatory and competitive uncertainties, and the need for careful patient enrichment for 007 trials. On balance, the operational and clinical progress and capitalization materially outweigh the listed challenges, but execution risk and competitive dynamics remain important near-term considerations.
On the call Wave provided concrete operational and clinical guidance and several key metrics: financials for Q1 2026 included $38.2M revenue, R&D expense $47.4M, G&A $22.1M, net loss $26.1M, and $544.6M cash expected to fund operations into Q3 2028; clinically, Wave plans to initiate the Phase IIa multiple‑dose portion of INLIGHT this quarter (Q2 2026) and to start INHBE combination and post‑incretin maintenance studies later in 2026; the Phase IIa is a global, placebo‑controlled trial enrolling BMI 35–50 patients with and without T2D across two doses (240 mg and 400 mg) in four cohorts of 40 patients each (160 total), with dosing on Day 1 and Day 85 and a 12‑month follow‑up (first main assessment at Day 85); Phase I 240 mg data show durable knockdown through ≥7 months with placebo‑adjusted visceral fat −14.3%, total fat −5.3%, waist circumference −3.3% and a VMR improvement of ~16.5% (vs semaglutide 12.2% and vimanrimab 18.8%); for RNA editing, WVE‑006 interim data demonstrated restoration of functional MAAT (including >20 μM AAT during an acute phase response) with 200 mg biweekly, Wave will present 400 mg monthly and single‑dose 600 mg data at ATS/May 18 and expects regulatory feedback on a potential accelerated approval pathway mid‑2026, and WVE‑008 is on track for a 2026 CTA submission.
Q1 2026 revenue of $38.2M versus $9.2M in Q1 2025, a ~315% year-over-year increase driven primarily by recognizing the full amount of revenue associated with regaining full rights to WVE-006 and progress in the GSK collaboration.
Net loss narrowed to $26.1M in Q1 2026 from $46.9M in Q1 2025 (a ~44% improvement). Company ended the quarter with $544.6M in cash and cash equivalents, which management expects will fund operations into Q3 2028.
Single-dose Phase I data (240 mg cohort, 6 months) showed placebo-adjusted visceral fat reduction of 14.3%, total fat reduction of 5.3%, waist circumference reduction of 3.3%, and stable lean mass. Durability demonstrated through at least 7 months supports potential once- or twice-year dosing.
Visceral fat-to-muscle ratio (VMR) improved by 16.5% with single-dose 007 — exceeding the 12.2% improvement reported for weekly semaglutide (BELIEVE) and approaching 18.8% observed with comparator vimanrimab — suggesting a differentiated body-composition signal focused on fat loss with muscle preservation.
FDA accepted the multi-dose portion of INLIGHT. Phase IIa to start this quarter with global, placebo-controlled multi-dose study enrolling participants BMI 35–50 (with and without T2D), two dose levels (240 mg and 400 mg), four cohorts of 40 patients each (total ~160). Dosing: two doses (Day 1 and Day 85) with 12-month follow-up and primary assessment at Day 85.
RestorA-2 interim and ongoing data demonstrate restoration of therapeutically relevant native M-AAT, including generation of >20 µM AAT during an acute phase response; 200 mg biweekly dosing previously restored endogenous MAAT to meaningful levels. Management expects regulatory feedback on a potential accelerated approval pathway mid-2026 and will present expanded 400 mg multiple-dose and 600 mg single-dose data at ATS (May 18).
WVE-008 (RNA editing for PNPLA3 I148M homozygotes) progressing toward a CTA submission in 2026 to address ~9 million homozygous carriers in US/EU. Company continuing to develop bifunctional constructs and both hepatic and extrahepatic candidates.
Management is advancing plans to test 007 in combination with incretins and as a maintenance therapy post-incretin this year, leveraging 007's orthogonal mechanism (targeted lipolysis) and muscle preservation to pursue combination and long-term maintenance use cases.
Hello, and welcome to Wave Life Sciences First Quarter 2026 Earnings Call. [Operator Instructions]. Also, as a reminder, this conference call is being recorded today. I will now turn the call over to Kate Rausch, Vice President of Corporate Affairs and Investor Relations.
Thank you, operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our first quarter 2026 earnings update. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer; Dr. Eric Ingelsson, Chief Scientific Officer; Dr. Chris Wright, Chief Medical Officer; and Kyle Moran, Chief Financial Officer. The press release issued this morning is available on the Investors section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements.
These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul.
Thanks, Kate, and good morning to everyone joining us on today's call. Coming into the year, we outlined our key priorities for 2026, accelerating development of WVE-007, our INHIBNE GalNAc siRNA program for obesity and rapidly advancing our RNA editi...